{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T17:02:37Z","timestamp":1784998957834,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100002551","name":"Seoul National University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100002551","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2026,8]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Purpose<\/jats:title>\n                    <jats:p>\n                      Epidermal growth factor receptor (\n                      <jats:italic>EGFR<\/jats:italic>\n                      ) amplification remains a controversial therapeutic biomarker. We report outcomes of erlotinib plus bevacizumab (E\u2009+\u2009B) in patients with\n                      <jats:italic>EGFR<\/jats:italic>\n                      -amplified metastatic solid tumors.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Patients with metastatic solid cancer who had progressed after standard therapies and were treated with E\u2009+\u2009B based on central molecular tumor board recommendations in the KOSMOS trial were included. Only those with an\n                      <jats:italic>EGFR<\/jats:italic>\n                      copy number\u2009\u2265\u20093 were selected. The primary endpoint was the clinical benefit rate (CBR), while secondary endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Between February 2021 and April 2024, 25 patients were treated with E\u2009+\u2009B (median EGFR copy 8.9; range, 3\u201376). Six tumor types were included, with colorectal cancer being the most prevalent (N\u2009=\u200914), followed by glioblastoma (N\u2009=\u20095), and other types (N\u2009=\u20096). Overall, four partial responses (PR) and seven cases of stable disease (SD) lasting over 16\u00a0weeks were observed, resulting in a CBR of 44.0% and ORR of 16%. The median PFS was 3.7\u00a0months (95% confidence interval [CI]: 1.7\u20134.6), whereas the median OS was 7.9\u00a0months (95% CI: 6.5 to not estimable). Six patients experienced one or more grade 3 adverse events related to E\u2009+\u2009B, including hypertension and mucositis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>\n                      The E\u2009+\u2009B combination showed modest anti-tumor activity in patients with heavily pretreated\n                      <jats:italic>EGFR<\/jats:italic>\n                      -amplified solid cancers. While NGS may help identify new applications for existing drugs, additional investigations are warranted to validate the efficacy and benefit of E\u2009+\u2009B in this population.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10147-026-03080-5","type":"journal-article","created":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T16:03:25Z","timestamp":1781539405000},"page":"1668-1677","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Erlotinib plus bevacizumab in EGFR-amplified metastatic solid tumors: results from the KOSMOS I, II study of molecular profiling\u2013guided therapy in advanced cancers"],"prefix":"10.1007","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4274-3633","authenticated-orcid":false,"given":"Jiwon","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jongmin","family":"Sim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yun-Gyoo","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gyeong-Won","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Ae","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyu-Pyo","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tae-Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyewon","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Min-Hee","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi-Sun","family":"Ahn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minsuk","family":"Kwon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhumsuk","family":"Keam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Mo","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheehyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harim","family":"Koo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sun Young","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jee Hyun","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9665-062X","authenticated-orcid":false,"given":"Soohyeon","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,15]]},"reference":[{"key":"3080_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.trecan.2020.08.009","volume":"7","author":"JJ Adashek","year":"2021","unstructured":"Adashek JJ, Subbiah V, Kurzrock R (2021) From tissue-agnostic to N-of-one therapies: (r)evolution of the precision paradigm. Trends Cancer 7:15\u201328. https:\/\/doi.org\/10.1016\/j.trecan.2020.08.009","journal-title":"Trends Cancer"},{"key":"3080_CR2","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1158\/1535-7163.MCT-15-0643","volume":"15","author":"ML Turski","year":"2016","unstructured":"Turski ML, Vidwans SJ, Janku F et al (2016) Genomically driven tumors and actionability across histologies: BRAF-mutant cancers as a paradigm. Mol Cancer Ther 15:533\u2013547. https:\/\/doi.org\/10.1158\/1535-7163.MCT-15-0643","journal-title":"Mol Cancer Ther"},{"key":"3080_CR3","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1200\/JCO.2014.56.2728","volume":"33","author":"B Kaufman","year":"2015","unstructured":"Kaufman B, Shapira-Frommer R, Schmutzler RK et al (2015) Olaparib monotherapy in patients with advanced cancer and a germline BRCA1\/2 mutation. J Clin Oncol 33:244\u2013250. https:\/\/doi.org\/10.1200\/JCO.2014.56.2728","journal-title":"J Clin Oncol"},{"key":"3080_CR4","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","volume":"378","author":"A Drilon","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S et al (2018) Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 378:731\u2013739. https:\/\/doi.org\/10.1056\/NEJMoa1714448","journal-title":"N Engl J Med"},{"key":"3080_CR5","doi-asserted-by":"publisher","DOI":"10.1200\/PO.17.00073","author":"R Bonneville","year":"2017","unstructured":"Bonneville R, Krook MA, Kautto EA et al (2017) landscape of microsatellite instability across 39 cancer types. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.17.00073","journal-title":"JCO Precis Oncol"},{"key":"3080_CR6","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1093\/jnci\/djz245","volume":"112","author":"KT Flaherty","year":"2020","unstructured":"Flaherty KT, Gray R, Chen A et al (2020) The molecular analysis for therapy choice (NCI-MATCH) trial: lessons for genomic trial design. J Natl Cancer Inst 112:1021\u20131029. https:\/\/doi.org\/10.1093\/jnci\/djz245","journal-title":"J Natl Cancer Inst"},{"key":"3080_CR7","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00122","author":"PK Mangat","year":"2018","unstructured":"Mangat PK, Halabi S, Bruinooge SS et al (2018) Rationale and design of the targeted agent and profiling utilization registry (TAPUR) study. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.18.00122","journal-title":"JCO Precis Oncol"},{"key":"3080_CR8","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.gene.2005.10.018","volume":"366","author":"N Normanno","year":"2006","unstructured":"Normanno N, De Luca A, Bianco C et al (2006) Epidermal growth factor receptor (EGFR) signaling in cancer. Gene 366:2\u201316. https:\/\/doi.org\/10.1016\/j.gene.2005.10.018","journal-title":"Gene"},{"key":"3080_CR9","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1038\/nrm1962","volume":"7","author":"A Citri","year":"2006","unstructured":"Citri A, Yarden Y (2006) EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol 7:505\u2013516. https:\/\/doi.org\/10.1038\/nrm1962","journal-title":"Nat Rev Mol Cell Biol"},{"key":"3080_CR10","doi-asserted-by":"publisher","first-page":"879","DOI":"10.2741\/e296","volume":"3","author":"G Bronte","year":"2011","unstructured":"Bronte G, Terrasi M, Rizzo S et al (2011) EGFR genomic alterations in cancer: prognostic and predictive values. Front Biosci (Elite Ed) 3:879\u2013887. https:\/\/doi.org\/10.2741\/e296","journal-title":"Front Biosci (Elite Ed)"},{"key":"3080_CR11","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2020.103811","volume":"99","author":"A Ayati","year":"2020","unstructured":"Ayati A, Moghimi S, Salarinejad S et al (2020) A review on progression of epidermal growth factor receptor (EGFR) inhibitors as an efficient approach in cancer targeted therapy. Bioorg Chem 99:103811. https:\/\/doi.org\/10.1016\/j.bioorg.2020.103811","journal-title":"Bioorg Chem"},{"key":"3080_CR12","doi-asserted-by":"publisher","first-page":"815","DOI":"10.2174\/1568026620666200303123102","volume":"20","author":"DA Sabbah","year":"2020","unstructured":"Sabbah DA, Hajjo R, Sweidan K (2020) Review on epidermal growth factor receptor (EGFR) structure, signaling pathways, interactions, and recent updates of EGFR inhibitors. Curr Top Med Chem 20:815\u2013834. https:\/\/doi.org\/10.2174\/1568026620666200303123102","journal-title":"Curr Top Med Chem"},{"key":"3080_CR13","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00180","author":"S Kato","year":"2019","unstructured":"Kato S, Okamura R, Mareboina M et al (2019) Revisiting epidermal growth factor receptor (EGFR) amplification as a target for anti-EGFR therapy: analysis of cell-free circulating tumor DNA in patients with advanced malignancies. JCO Precis Oncol. https:\/\/doi.org\/10.1200\/PO.18.00180","journal-title":"JCO Precis Oncol"},{"key":"3080_CR14","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1158\/2159-8290.CD-17-1260","volume":"8","author":"SB Maron","year":"2018","unstructured":"Maron SB, Alpert L, Kwak HA et al (2018) Targeted therapies for targeted populations: Anti-EGFR treatment for EGFR-amplified gastroesophageal adenocarcinoma. Cancer Discov 8:696\u2013713. https:\/\/doi.org\/10.1158\/2159-8290.CD-17-1260","journal-title":"Cancer Discov"},{"key":"3080_CR15","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1007\/s00432-009-0622-4","volume":"135","author":"B Zahorowska","year":"2009","unstructured":"Zahorowska B, Crowe PJ, Yang JL (2009) Combined therapies for cancer: a review of EGFR-targeted monotherapy and combination treatment with other drugs. J Cancer Res Clin Oncol 135:1137\u20131148. https:\/\/doi.org\/10.1007\/s00432-009-0622-4","journal-title":"J Cancer Res Clin Oncol"},{"key":"3080_CR16","doi-asserted-by":"publisher","first-page":"204","DOI":"10.7150\/ijbs.22955","volume":"14","author":"Z Yang","year":"2018","unstructured":"Yang Z, Tam KY (2018) Combination strategies using EGFR-TKi in NSCLC therapy: learning from the gap between pre-clinical results and clinical outcomes. Int J Biol Sci 14:204\u2013216. https:\/\/doi.org\/10.7150\/ijbs.22955","journal-title":"Int J Biol Sci"},{"key":"3080_CR17","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1158\/1541-7786.MCR-06-0404","volume":"5","author":"J Tabernero","year":"2007","unstructured":"Tabernero J (2007) The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5:203\u2013220. https:\/\/doi.org\/10.1158\/1541-7786.MCR-06-0404","journal-title":"Mol Cancer Res"},{"key":"3080_CR18","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1016\/S1470-2045(19)30035-X","volume":"20","author":"H Saito","year":"2019","unstructured":"Saito H, Fukuhara T, Furuya N et al (2019) Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. Lancet Oncol 20:625\u2013635. https:\/\/doi.org\/10.1016\/S1470-2045(19)30035-X","journal-title":"Lancet Oncol"},{"key":"3080_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2024.103709","volume":"9","author":"TY Kim","year":"2024","unstructured":"Kim TY, Kim SY, Kim JH et al (2024) Nationwide precision oncology pilot study: Korean precision medicine networking group study of MOlecular profiling-guided therapy based on genomic alterations in advanced solid tumors (KOSMOS) KCSG AL-20-05. ESMO Open 9:103709. https:\/\/doi.org\/10.1016\/j.esmoop.2024.103709","journal-title":"ESMO Open"},{"key":"3080_CR20","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1200\/JOP.2015.009407","volume":"12","author":"M Dhir","year":"2016","unstructured":"Dhir M, Sasson AR (2016) Surgical management of liver metastases from colorectal cancer. J Oncol Pract 12:33\u201339. https:\/\/doi.org\/10.1200\/JOP.2015.009407","journal-title":"J Oncol Pract"},{"key":"3080_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2147\/LCTT.S10167","volume":"2","author":"S Ricciardi","year":"2011","unstructured":"Ricciardi S, Tomao S, de Marinis F (2011) Efficacy and safety of erlotinib in the treatment of metastatic non-small-cell lung cancer. Lung Cancer (Auckl) 2:1\u20139. https:\/\/doi.org\/10.2147\/LCTT.S10167","journal-title":"Lung Cancer (Auckl)"},{"key":"3080_CR22","doi-asserted-by":"publisher","first-page":"2458","DOI":"10.1200\/JCO.21.02453","volume":"40","author":"SB Maron","year":"2022","unstructured":"Maron SB, Moya S, Morano F et al (2022) Epidermal growth factor receptor inhibition in epidermal growth factor receptor-amplified gastroesophageal cancer: retrospective global experience. J Clin Oncol 40:2458\u20132467. https:\/\/doi.org\/10.1200\/JCO.21.02453","journal-title":"J Clin Oncol"},{"key":"3080_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/S1470-2045(05)70102-9","volume":"6","author":"M Moroni","year":"2005","unstructured":"Moroni M, Veronese S, Benvenuti S et al (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279\u2013286. https:\/\/doi.org\/10.1016\/S1470-2045(05)70102-9","journal-title":"Lancet Oncol"},{"key":"3080_CR24","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3978\/j.issn.1000-9604.2014.01.10","volume":"26","author":"WD Shen","year":"2014","unstructured":"Shen WD, Chen HL, Liu PF (2014) EGFR gene copy number as a predictive biomarker for resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer treatment: a meta-analysis. Chin J Cancer Res 26:59\u201371. https:\/\/doi.org\/10.3978\/j.issn.1000-9604.2014.01.10","journal-title":"Chin J Cancer Res"},{"key":"3080_CR25","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1158\/1078-0432.CCR-1100-03","volume":"10","author":"F Ciardiello","year":"2004","unstructured":"Ciardiello F, Bianco R, Caputo R et al (2004) Antitumor activity of ZD6474, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in human cancer cells with acquired resistance to antiepidermal growth factor receptor therapy. Clin Cancer Res 10:784\u2013793. https:\/\/doi.org\/10.1158\/1078-0432.CCR-1100-03","journal-title":"Clin Cancer Res"},{"key":"3080_CR26","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-016-2834-8","volume":"16","author":"C Ding","year":"2016","unstructured":"Ding C, Li L, Yang T et al (2016) Combined application of anti-VEGF and anti-EGFR attenuates the growth and angiogenesis of colorectal cancer mainly through suppressing AKT and ERK signaling in mice model. BMC Cancer 16:791. https:\/\/doi.org\/10.1186\/s12885-016-2834-8","journal-title":"BMC Cancer"},{"key":"3080_CR27","doi-asserted-by":"publisher","first-page":"2279","DOI":"10.1200\/JCO.2016.70.3934","volume":"35","author":"RD Petty","year":"2017","unstructured":"Petty RD, Dahle-Smith A, Stevenson DAJ et al (2017) Gefitinib and EGFR gene copy number aberrations in esophageal cancer. J Clin Oncol 35:2279\u20132287. https:\/\/doi.org\/10.1200\/JCO.2016.70.3934","journal-title":"J Clin Oncol"},{"key":"3080_CR28","doi-asserted-by":"publisher","first-page":"2526","DOI":"10.1093\/annonc\/mdx344","volume":"28","author":"EEW Cohen","year":"2017","unstructured":"Cohen EEW, Licitra LF, Burtness B et al (2017) Biomarkers predict enhanced clinical outcomes with afatinib versus methotrexate in patients with second-line recurrent and\/or metastatic head and neck cancer. Ann Oncol 28:2526\u20132532. https:\/\/doi.org\/10.1093\/annonc\/mdx344","journal-title":"Ann Oncol"},{"key":"3080_CR29","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1158\/2159-8290.CD-11-0109","volume":"1","author":"A Bertotti","year":"2011","unstructured":"Bertotti A et al (2011) A molecularly annotated platform of patient-derived xenografts (\u201cxenopatients\u201d) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 1:508\u2013523. https:\/\/doi.org\/10.1158\/2159-8290.CD-11-0109","journal-title":"Cancer Discov"},{"key":"3080_CR30","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3002442","volume":"3","author":"K Yonesaka","year":"2011","unstructured":"Yonesaka K et al (2011) Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody Cetuximab. Sci Transl Med 3:99ra86. https:\/\/doi.org\/10.1126\/scitranslmed.3002442","journal-title":"Sci Transl Med"},{"key":"3080_CR31","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1016\/j.ejca.2013.07.007","volume":"49","author":"M Xie","year":"2013","unstructured":"Xie M et al (2013) Notch-1 contributes to epidermal growth factor receptor tyrosine kinase inhibitor acquired resistance in non-small cell lung cancer in vitro and in vivo. Eur J Cancer 49:3559\u20133572. https:\/\/doi.org\/10.1016\/j.ejca.2013.07.007","journal-title":"Eur J Cancer"},{"key":"3080_CR32","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1056\/NEJMoa1414325","volume":"372","author":"RJ Mayer","year":"2015","unstructured":"Mayer RJ, Van Cutsem E, Falcone A et al (2015) Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 372:1909\u20131919. https:\/\/doi.org\/10.1056\/NEJMoa1414325","journal-title":"N Engl J Med"},{"key":"3080_CR33","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A et al (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381:303\u2013312. https:\/\/doi.org\/10.1016\/S0140-6736(12)61900-X","journal-title":"Lancet"},{"key":"3080_CR34","doi-asserted-by":"publisher","first-page":"1300","DOI":"10.1093\/neuonc\/noq099","volume":"12","author":"S Sathornsumetee","year":"2010","unstructured":"Sathornsumetee S, Desjardins A, Vredenburgh JJ et al (2010) Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 12:1300\u20131310. https:\/\/doi.org\/10.1093\/neuonc\/noq099","journal-title":"Neuro Oncol"},{"key":"3080_CR35","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.1093\/neuonc\/nox105","volume":"19","author":"JM Sepulveda-Sanchez","year":"2017","unstructured":"Sepulveda-Sanchez JM, Vaz MA, Balana C et al (2017) Phase II trial of dacomitinib, a pan-human EGFR tyrosine kinase inhibitor, in recurrent glioblastoma patients with EGFR amplification. Neuro Oncol 19:1522\u20131531. https:\/\/doi.org\/10.1093\/neuonc\/nox105","journal-title":"Neuro Oncol"},{"key":"3080_CR36","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1093\/neuonc\/noq072","volume":"12","author":"WKA Yung","year":"2010","unstructured":"Yung WKA, Vredenburgh JJ, Cloughesy TF et al (2010) Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 12:1061\u20131070. https:\/\/doi.org\/10.1093\/neuonc\/noq072","journal-title":"Neuro Oncol"},{"key":"3080_CR37","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1200\/JCO.2004.08.110","volume":"22","author":"JN Rich","year":"2004","unstructured":"Rich JN, Reardon DA, Peery T et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133\u2013142. https:\/\/doi.org\/10.1200\/JCO.2004.08.110","journal-title":"J Clin Oncol"},{"key":"3080_CR38","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1158\/1078-0432.CCR-06-2372","volume":"13","author":"A Broniscer","year":"2007","unstructured":"Broniscer A, Panetta JC, O\u2019Shaughnessy M et al (2007) Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420. Clin Cancer Res 13:1511\u20131515. https:\/\/doi.org\/10.1158\/1078-0432.CCR-06-2372","journal-title":"Clin Cancer Res"},{"key":"3080_CR39","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1007\/s40262-015-0319-6","volume":"55","author":"MO Jacus","year":"2016","unstructured":"Jacus MO, Daryani VM, Harstead KE et al (2016) Pharmacokinetic properties of anticancer agents for the treatment of central nervous system tumors: update of the literature. Clin Pharmacokinet 55:297\u2013311. https:\/\/doi.org\/10.1007\/s40262-015-0319-6","journal-title":"Clin Pharmacokinet"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03080-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-026-03080-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-026-03080-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T16:35:44Z","timestamp":1784997344000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-026-03080-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,15]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["3080"],"URL":"https:\/\/doi.org\/10.1007\/s10147-026-03080-5","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,15]]},"assertion":[{"value":"4 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflicts of interest related to this work.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The KOSMOS and KOSMOS-II studies were conducted in accordance with the Declaration of Helsinki and were approved by the institutional review boards of all participating centers.","order":2,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from all patients prior to enrollment. Consent for publication of clinical details and images was also obtained from all participants.","order":3,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}}]}}